tbuckley/cabot-search huggingface dataset:
Molecular and cytogenetic characterization of the 3q25-q27 amplification unit reveals TLOC1/SEC62 as a putative oncogene in prostate cancer
Authors: Jung Volker, Roland Kindich, Joern Kamradt, Martin Jung, Mirko Muller, Wolfgang Schulz, Rainer Engers, Michael Stockle, Richard Zimmermann, Bernd Wullich
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

2565 

Purpose: In prostate carcinomas, gene amplifications (e.g. c-MYC, HER2/NEU, androgen receptor gene) have been found and being related to progressive tumor growth. Using comparative genomic hybridization (CGH), we recently detected DNA copy number gains at chromosome 3q25-q27 in 35% of analyzed tumor samples. In the present study, we set out to further characterize this amplicon by cytogenetic and molecular genetic techniques and to identify a probable target gene. Material and Methods: Prostate carcinoma cell lines (PC3, DU145, DU145MN1) and 22 tumor samples from radical prostatectomy specimens were screened for chromosomal aberrations with CGH. To narrow down the amplification unit, 26 overlapping BAC clones covering the 3q amplicon were hybridized on the prostate carcinoma cell lines. DNA copy number changes of 6 candidate genes (hTERC, SAMD7, TLOC1/SEC62, SKIL, SLC2A2, PIK3CA) located within the BAC clones with the highest copy-number status were analyzed using a modified quantification assay based on the LightCycler™ system. Additionally, mRNA expression levels of these genes were measured using relative real time PCR quantification. Results: The 3q amplicon could be narrowed down to 700 kb at 3q26.2. Positional and functional candidates revealed the following amplification frequencies in the primary tumor samples: hTERC 9%, SAMD7 32%, TLOC1/SEC62 59%, SKIL 0%, SLC2A2 27%, PIK3CA 9%. Interestingly, TLOC1/SEC62 with the highest amplification frequency showed a 3-14 fold overexpression in the 13 prostate carcinomas analyzed compared to normal prostate fibroblasts. TLOC1/Sec62-p was also demonstrated to be overexpressed by western blot analysis. Conclusions: Using molecular cytogenetic techniques, we identified TLOC1/SEC62 as the best candidate within the 3q amplification unit in prostate cancer. Intriguingly, the TLOC1/SEC62 gene copy number was increased in prostate tumors from patients, who had a lower risk of and a longer time to progression following radical prostatectomy. TLOC1/Sec62 protein is a component of the endoplasmic reticulum and is supposed to be active in a dual manner as part of the protein translocase complex and as a calcium ion channel. Supported by Deutsche Krebshilfe: 70-2936 Wu I
Cyclosporine and Methotrexate Compared with Cyclosporine and Mycophenolate Mofetil as GVHD Prevention Regimens In Allogeneic Stem-Cell Transplantation From Unrelated Donors; Relative Outcomes Are Dependant on Disease Status at Transplantation
Authors: Avichai Shimoni, Avital Rand, Noga Shem-Tov, Izhar Hardan, Yulia Volchek, Ronit Yerushalmi, Arnon Nagler
Journal: Blood (2010)
Diet-Microbiome Interactions in Health Are Controlled by Intestinal Nitrogen Source Constraints
Authors: Andrew J. Holmes, Yi Vee Chew, Feyza Colakoglu, John B. Cliff, Eline Klaassens, Mark N. Read, Samantha M. Solon-Biet, Aisling C. McMahon, Victoria C. Cogger, Kari Ruohonen, David Raubenheimer, David G. Le Couteur, Stephen J. Simpson
Journal: Cell Metabolism (2016)
THU0111 Biologics Discontinuation and BMI Predict RA Flare Risk after Hip and Knee Arthroplasty: Table 1.
Authors: S.M. Goodman, S.J. Bartlett, R.W. Cummings, K.M. Andersen, L.T. Donlin, D.E. Orange, A. Hoang, M.P. Figgie, V.P. Bykerk
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Immunosuppressive medications are often stopped prior to arthroplasty to mitigate infection risk, but this may increase the risk of disease flares post surgery in patients with rheumatoid arthritis (RA). <h3>Objectives</h3> To describe rates, characteristics, and risk factors for flare after total hip (THA) and total knee (TKA) arthroplasty surgery. <h3>Methods</h3> Pre- and post-operative characteristics were examined in 58 RA patients undergoing TKA/THA. Perioperative medication use was standard of care: biologics were stopped before surgery, while steroids and methotrexate (MTX) continued. Clinicians evaluated RA clinical characteristics, on average, 0–2 weeks before and 6 weeks post-surgery. Post-surgery, patients completed weekly questions about RA symptoms, impact, and flare status using the OMERACT Flare Questionnaire. Baseline characteristics were compared using t-tests and chi-square, and multivariate logistic regression was used to identify baseline characteristics associated with post-surgical RA flares. <h3>Results</h3> Of 68 patients, 10 (15%) were flaring prior to surgery and were excluded. 88% met 2010/1987 RA criteria; those who did not meet criteria were included by rheumatologist diagnosis. Patients had a mean [SD] age of 61 [12], BMI of 30.6 [7.2], and RA duration of 16 [12] yrs. 59 (87%) were female, 53 (78%) were white, 33 (49%) were having THA, and 35 (52%) were on biologics. 35 (60%) had flared by 6 weeks post surgery. At baseline, flarers had significantly (p&lt;.05) higher BMI, higher disease activity indicators (DAS28, RAPID3), inflammatory markers (ESR, CRP), and pain, and more were undergoing THA and used biologics (Table 1). After controlling for age, surgical joint, and baseline DAS28, the odds of flaring by 6 weeks post-surgery were significantly higher in patients who had discontinued biologics (OR 14.9, 95% CI 2.0, 112.0) or were obese (OR 6.0, 95% CI 1.1, 33.0). <h3>Conclusions</h3> Flares are frequent in RA patients undergoing arthroplasty, particularly THA. Discontinuing biologics and obesity significantly increased the risk of flaring post-arthroplasty. <h3>Acknowledgement</h3> This study was supported by the Clinical Translational Science Center (CTSC) (UL1-TR000457–06). <h3>Disclosure of Interest</h3> None declared
SAT0581 Cost Savings with Biosimilars in Rheumatology: A Systematic Literature Search of Budget Impact Analysis: Table 1
Authors: F. Araújo, J. Gonçalves, J. Eurico Fonseca
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The growing use of biological therapies in immune-mediated rheumatic diseases represents a significant burden to healthcare systems struggling with tighter budgets. <h3>Objectives</h3> Our aim was to assess potential cost savings associated with the use of biosimilar anti-rheumatic therapies. <h3>Methods</h3> We performed a systematic literature search in the Medline database as well as EULAR, ACR and ISPOR meeting abstracts to identify budget impact analysis on biosimilars of infliximab (IFX), etanercept (ETA) and adalimumab (ADA) used in the treatment of rheumatic diseases. We included articles and abstracts published from 2013 onwards. <h3>Results</h3> We screened 195 articles by title and abstract and 2 publications fulfilled our inclusion criteria, both concerning IFX. Five abstracts were also included (2 on ETA, 2 on IFX and 1 on IFX+ETA+ADA). Five studies performed the analysis on rheumatoid arthritis and the other 2 also in spondyloarthritis, psoriasis and inflammatory bowel disease. The heterogeneity of budget impact models didn9t allow for direct comparisons but all studies pointed out significant cost savings, from dozens to thousands of millions of euros, depending on the countries analysed, time horizon, discount scenarios and biosimilar uptake shares. The reinvestment of biosimilar-related savings would also allow for the treatment of thousands of additional rheumatic patients. The authors of these models stress, however, that some of the assumptions made may not reflect real-world scenarios. Table 1 summarizes the main findings in the included studies. <h3>Conclusions</h3> The use of biosimilar anti-rheumatic therapies may represent a strategy to reduce drug-related expenditure and contribute to financial sustainability of healthcare systems worldwide. <h3>Disclosure of Interest</h3> F. Araújo Consultant for: Pfizer, J. Gonçalves Grant/research support from: MSD, UCB and Hospira, Consultant for: MSD, AbbVie, Novartis, Sandoz, Hospira, Celltrion, Janssen Pharmaceuticals, Eli Lilly, Roche and Merck, J. Eurico Fonseca Grant/research support from: Abbvie, Amgen, BMS, Celtrion, Celgene, Eli Lilly, Hospira, Janssen, Mundipharma, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Servier, UCB, Consultant for: Abbvie, Amgen, BMS, Celtrion, Celgene, Eli Lilly, Hospira, Janssen, Mundipharma, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Servier, UCB
AB0521 Quality of Life in Patients with Sle and Cutaneous Involvement
Authors: V. Sadovici-Bobeica, M. Cebanu, L. Mazur-Nicorici, V. Salaru, M. Pasali, M. Mazur
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To establish the relationship between cutaneous involvement and Quality of Life (QoL) in patients with systemic lupus erythematosus <h3>Methods</h3> Cross-sectional study of SLE patients with cutaneous involvement, fulfilling SLICC/ACR 2012 classification criteria. Cutaneous involvement was assessed by Cutaneous Lupus Erithematosus Disease Area and Severity Index (CLASI), disease activity – by SLEDAI and SLAM and QoL by SF-8 questionnaire. The Pearson correlation coefficient was calculated between the variables. <h3>Results</h3> The study included 92 Caucasian SLE female patients with a mean age of 40,0±12,6 yrs and a mean disease duration of 5,1±5,8 yrs. The mean age at the disease onset was 33,5±11,4 yrs and the mean SLICC/ACR criteria number – 6,1±2,8 points. The disease activity by SLEDAI and SLAM was appreciated as high with 1,24±10,4 and 12,1±8,6 points, respectively. The SLICC/ACR DI constituted 1,47±1,6 points. The cutaneous involvment by CLASI showed a mean activity of 4,7 points and a damage of 3,0 points, mean CLASI score being appreciated with 7,2 points. The QoL by SF-8 demonstrated low indices, compared to general population, in both domains: Physical Component Summary (PCS) and Mental Component Summary (MCS) with a mean value of 37,74 and 38,72 points, respectively. The analysis of Pearson coefficient between the QoL and CLASI did not show significant correlation (r≤0,2, p&gt;0,05). The PCS og the QoL correlated inversely with the disease activity (r=-0,58 for SLAM and r=-0,45 for SLEDAI, p&lt;0,05) and the MCS correlated inversely with SLICC/ACR classificatino criteria (r=-0,45, p&lt;0,05). CLASI activity index correlated with SLAM and SLEDAI (r=0,45 for SLAM and r=0,37 for SLEDAI). <h3>Conclusions</h3> The QoL is dicreased in SLE patients by both components: physical and mental. The severity of cutaneous involvment did not correlate with the QoL9s indices. Meantime, CLASI activity score correlated with disease activity and the MCP pf the QoL correlated with the number of SCLICC/ACR 2012 classification criteria. <h3>Disclosure of Interest</h3> None declared
Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes
Authors: Cameron J Turtle, Carolina Berger, Daniel Sommermeyer, Laila-Aicha Hanafi, Barbara Pender, Emily M Robinson, Katherine Melville, Tanya M Budiarto, Natalia N Steevens, Colette Chaney, Sindhu Cherian, Brent L Wood, Lorinda Soma, Xueyan Chen, Shelly Heimfeld, Michael C Jensen, Stanley R. Riddell, David G Maloney
Journal: Blood (2015)
PTU-076 Bile Sampling to Ensure Appropriate Antibiotic Treatment of Infection in Patients Undergoing Percutaneous Transhepatic Cholangiography and Biliary Drainage
Authors: A Thind, A Allouni, R Uberoi
Journal: Gut (2016)

<h3>Introduction</h3> Biliary sepsis and cholangitis are frequent complications of percutaneous transhepatic cholangiography and biliary drainage (PTCBD). Due to bacterial resistance, biliary infection is often difficult to eradicate. The aims of this audit were to evaluate the frequency of bile sample collection during PTCBD for culture and antibiotic sensitivity tests. Further, whether antibiotic management of biliary infections post-procedure are appropriate. <h3>Methods</h3> A retrospective review of electronic patient records were conducted for 138 patients that underwent PTCBD for management of malignant biliary obstruction from 2012–2015 in the Interventional Radiology departments of the Oxford University Hospitals NHS Trust. Due to limitations of the electronic system, drug histories were only accessible from the 45 patients that underwent PTCBD in 2015. <h3>Results</h3> Of the 138 patients, 36% had samples cultured during the procedure. Of the positive bile samples, 61% had antibiotic sensitivities reported. Organisms identified included mixed faecal flora (33%), anaerobes (12%), aerobic gram-positive cocci (23%), aerobic gram-negative (14%), Pseudomonas (7%) and Candida (7%). In 2015, 53% that underwent PTCBD received antibiotics for biliary infection, of these, 46% had bile cultures and of the positive samples, 33% were tested for antibiotic sensitivity. Antibiotics administered included: amoxicillin/clavulanic acid (30%), metronidazole (33%), gentamycin (14%), piperacillin/tazobactam (9%), ceftriaxone (9%), ciprofloxacin (5%). <h3>Conclusion</h3> Thus, antibiotics to treat biliary infection following PTCBD are often prescribed without knowledge of the infective organism or its resistance and therefore may not be appropriate. Additionally, many of the treatments administered do not provide complete coverage of organisms identified in bile, notably Pseudomonas and Candida. Bile sample collection during PTCBD should become a standard procedure to delineate infective organisms and drug susceptibilities, hence driving a more targeted treatment in the event of biliary infection post-procedure, which may reduce mortality and costs associated with bacterial resistance. <h3>Disclosure of Interest</h3> None Declared
Deletions of the Derivative Chromosome 9 Do Not Influence Response to Imatinib of Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis).
Authors: Fausto Castagnetti, Giulia Marzocchi, Simona Luatti, Francesca Buontempo, Carmen Baldazzi, Francesca Palandri, Panagiota Giannoulia, Marilina Amabile, Ilaria Iacobucci, Marco Mancini, Ursula Giussani, Giorgina Specchia, Antonio Cuneo, Emilia Gugliano, Simonetta Kerim, Bruno Modaferri, Elisabetta Abruzzese, Giovanni Martinelli, Nicoletta Testoni, Gianantonio Rosti, Michele Baccarani
Journal: Blood (2006)
SP0199 Developments in EULAR Educational Projects in Ultrasound
Authors: E. Naredo
Journal: Annals of the Rheumatic Diseases (2016)

Over the last two decades, an increasing number of rheumatologists have progressively incorporated musculoskeletal ultrasound (MSUS) as a valuable diagnostic and monitoring tool in their clinical practice and research. US is also expanding its applications to new anatomic regions of importance in rheumatologic practice such as large vessels, salivary glands, ligaments, and peripheral nerves. In the first decade of the 21st century, the increasing utility of MSUS in rheumatology has led to a great demand for appropriate education in this imaging modality among rheumatologists worldwide. The European League Against Rheumatism (EULAR) has promoted for many years education in MSUS among rheumatologists in Europe and other continents. The EULAR has supported many educational projects in MSUS such as the development of the content and conduct of a high-quality multi-level MSUS training programme that culminates with a competency assessment systems for rheumatologic MSUS. In addition, EULAR qualifies European centres to become part of a network of Imaging training centres which includes MSUS. Currently EULAR is developing an Imaging Library that will offer images from the wide spectrum of imaging modalities used in rheumatology for the purpose of learning or teaching. <h3>Disclosure of Interest</h3> None declared
Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study.
Authors: Ivana Micallef, Patrick J. Stiff, John F. DiPersio, Richard Thomas Maziarz, John M. McCarty, Jennifer Angell, Gary Bridger, Gary Calandra
Journal: Blood (2007)
PWE-030 The Inflammatory Bowel Disease (IBD) Audit Programme at The Royal College of Physcians Reports on 10 Years of Achievements and Demonstrates Improvements in Care Of People with IBD
Authors: SM Murray, K Mortier
Journal: Gut (2016)

<h3>Introduction</h3> The IBD audit programme, first established in 2004 has conducted several rounds of audit. The programme’s aim is to improve the care of people with IBD by; facilitating the collection of key aspects of data on patient care and organisational services, analysing and disseminating the results, providing recommendations for improvements based on the key findings in the analyses. <h3>Methods</h3> Since 2006 the programme has facilitated up to 4 rounds of data collection on adults and children for inpatient care, organisation of IBD services and administration of biological therapies. We also collected data on patients experiences of care and the provision of care in primary care services. In 2015 the programme team hosted 8 regional workshops and proactively helped hospital IBD teams to develop action plans on key aspects of care that required improvements in their local areas. <h3>Results</h3> Over the 10 years of the programme’s work - a high level of participation in the audit has been achieved, &gt;90% participation rate from IBD hospital teams across the UK. There have been many improvements in patient care, the most notable since 2006 to date, are a reduction in mortality during admissions, reduction in unplanned surgery, increased patient contact with an IBD nurse, improved rates of prescribing heparin and bone protection. From the biological therapies audit, results clearly demonstrate biological therapies for IBD are effective and safe treatments. Patterns of prescribing are changing with earlier use in patients with less severe disease suggesting doctors have become more familiar with the treatment. Despite the positive improvements, the most recent audit, reported in 2014, identified that there were still aspects of care requiring improvements including treatment of anaemia, access to dietetic support and management of people attending out patient care. Also, the two audits on patient experience between 2010 and 2012 showed no improvements in patient’s experiences of care. The 8 regional workshops hosted in 2015 across the UK proved to be a successful initiative. They were attended by 84 trusts and healthcare boards. 74% of delegates surveyed at 6 months agreed that these had helped them to improve their service. <h3>Conclusion</h3> 10 years of intensive working and engagement with the IBD community, the programme could not boast of its achievements without acknowledging the support of the community. However further and continued improvements in patient care for people with IBD are necessary. In 2016 the IBD audit programme will be transitioning to the UK IBD Registry. There will be a continued emphasis to help hospital teams to make continued improvements in the quality of care of people with IBD through a number of initiatives. <h3>Disclosure of Interest</h3> None Declared
Long Term Outcomes after Autologous Stem Cell Transplantation for Peripheral T Cell Lymphomas
Authors: Deepa Jagadeesh, Lisa Rybicki, Donna M Abounader, Brian T. Hill, Robert M Dean, Hien K. Duong, Ronald M. Sobecks, Betty K. Hamilton, Aaron Gerds, Christina Ferraro, Gina Green, Kelly Cherni, Brad Pohlman, Matt E. Kalaycio, Brian J. Bolwell, Navneet S. Majhail
Journal: Blood (2014)
Favorable Outcome of Primary Mediastinal Large B-Cell Lymphoma Patients Treated with Sequential R-CHOP/R- ICE Regimen Omitting Radiation
Authors: Neta Goldschmidt, Ora B. Paltiel, Dina Ben Yehuda, Geffen Kleinstern, Alexander Gural, Diana Libster, David Lavie, Moshe E. Gatt
Journal: Blood (2015)
Public will have to “put their hands in their pockets” for better NHS, says Stevens
Authors: Abi Rimmer
Journal: BMJ (2016)

People will need to pay more if they want to see continued growth and improvement in the NHS, the chief executive of NHS England has said.

Speaking at the annual conference of the health think tank the King’s Fund in London on Wednesday 9 November, Simon Stevens was asked about the possibility of rationing NHS services. He said that he would have to be “persuaded of the benefits” of limiting healthcare but that the public might need to pay more in the future for improvements to services.

“I, and others, are being as clear as we …
Abstract 13763: Peri-Procedual Myocardial Injury Does not Correlate with Resistance of On-Clopidogrel Platelet Aggregation in Elective Percutaneous Coronary Intervention
Authors: Hiromi Yoshimura, Koichi Kaikita, Takamichi Ono, Naoki Nakayama, Koji Sato, Eiji Horio, Kenichi Tsujita, Seiji Hokimoto, Seigo Sugiyama, Hisao Ogawa
Journal: Circulation (2012)

The Joint ESC/ACCF/AHA/WHF Task Force has reported the definition of percutaneous coronary intervention (PCI)-related myocardial infarction in patients with normal baseline cardiac biomarker levels. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is shown to reduce increased risk of events after PCI. However, there is no report showing the relation between PCI-related peri-procedual myocardial injury (PMI) and the resistance of on-clopidogrel residual platelet aggregation (RPA) in patients undergoing elective PCI. We measured serial changes of plasma high-sensitive troponin T (hs-TnT) levels and RPA induced by ADP using light transmittance aggregometry in 108 patients undergoing PCI (PCI group). Thirty patients who did not receive PCI were enrolled as control group. Blood samples were obtained before, 24, and 48 hours after PCI, or before and 24 hours after coronary angiography (CAG) in control group. PMI was defined as plasma hs-TnT levels 24 hours after PCI greater than 3×99th percentile URL of hs-TnT levels. Plasma hs-TnT levels were identical before and 24 hours after CAG in control group. Plasma hs-TnT levels were significantly higher 24 hours after PCI compared with before PCI (17.9±14.5 vs. 86.8±121.5 pg/ml, P<0.003). Plasma hs-TnT levels peaked at 24 hours after PCI and returned close to baseline levels at 4 weeks after PCI. PMI were observed in 41 (45%) out of 108 patients. Simple logistic analysis revealed that PMI were correlated with age [odds ratio (OR) 2.48; 95% confidence interval (CI): 1.01 to 6.07; p=0.044], estimated glomerular filtration rate (OR 3.81; 95% CI: 1.51 to 9.61; p=0.004), hemoglobin (OR 2.74; 95% CI: 1.17 to 6.43; p=0.019) and stent length (OR 5.01; 95% CI: 2.01 to 12.47; p=0.001), respectively. Multiple logistic regression analysis identified the stent length as the significant and independent predictors of PMI (odds ratio 4.36; 95% CI: 1.68 to 11.36; p=0.0026). PMI did not influence the short-term major cardiac and cerebrovascular events during the 6 months follow-up period. In conclusion, PMI did not correlate with high on-clopidogrel RPA in elective PCI. The present study suggests that only PCI procedure but not the other factors including high on-clopidogrel RPA might predict PMI after elective PCI.